Compare Supplements

INVESTIGATIONAL — NO approved or consumer dose. In trials, efpeglenatide was given as a once-weekly subcutaneous injection, titrated up to 4-6 mg (AMPLITUDE-O used 4 and 6 mg) with gradual escalation to limit GI side effects. Not for self-administration; it is an unapproved, unmarketed investigational drug.

Any time

Once-weekly subcutaneous injection (investigational only)

Off-label use mirrors approved dosing (10–25 mg once daily in the morning) under a clinician. A prescription drug; not an approved longevity regimen.

Morning

Oral tablet (empagliflozin)

• Not a dietary supplement and not an approved/marketed drug — investigational; do not self-source grey-market vials
• Personal/family history of medullary thyroid carcinoma or MEN 2 (expected GLP-1-class thyroid C-cell warning)
• History of pancreatitis

• Oral medications (delayed gastric emptying)
• Insulin / insulin secretagogues (sulfonylureas)
• Other GLP-1 / incretin drugs

• Type 1 diabetes (ketoacidosis risk)
• Severe renal impairment per label / dialysis
• History of recurrent diabetic ketoacidosis

• Diuretics
• Insulin / sulfonylureas